http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6291534-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 |
| filingDate | 1998-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2001-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7eb53a12aa2b3b55ae9622e30c55d5fc |
| publicationDate | 2001-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-6291534-B1 |
| titleOfInvention | Chemical entity (endipalene) in the treatment of psoriasis |
| abstract | In the literature, a correlation between the inhibition of 5-lipoxygenase and anti-inflammatory and immunomodulatory activity sufficient to effectively treat psoriasis, is known. It seems that, in particular, the excellent results can be obtained with lonapalene (6-chloro-2,3-dimethoxynaphthalendioldiacetate). However, the clinical use of lonapalene has not been successful most likely due to the significant number of side effects. With these considerations, after various studies, we have identified a molecule which we have patented with the name of endipalene, which seems to guarantee notable therapeutic results without side effects. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3791880-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4008327-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011105624-A1 |
| priorityDate | 1997-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.